Introduction
The enzyme cytochrome P450 aromatase is a microsomal protein which catalyses the final stage of estrogen biosynthesis pathway from its androgen substrate. The aromatase is encoded by the CYP19 gene characterized by several untranslated exons which expression lies on alternative promoters submitted to a tissue-specific regulation (1) . The enzyme is widely expressed in steroidogenic tissues such as gonads and placenta but also in adipose tissue, brain and bone which are able to synthesize estrogens (2) . There is indirect evidence that the normal human adrenal cortex is also a source for estrogen production (3, 4) but the molecular mechanisms assigned in such biosynthesis are still poorly characterized. Aromatase is expressed in the human adrenal medulla at all stages from postnatal until pubertal, but only the zona glomerulosa expresses the enzyme in the postadrenarche period (5) . Aromatase is overexpressed in feminizing adrenocortical tumors (6-10) but its expression was not yet investigated, to our knowledge, in non-feminizing tumors of adrenal origin. The aim of the present study was to evaluate the aromatase enzyme activity and CYP19 gene expression level in the normal adrenal cortex and in adrenal feminizing tumors together with other steroid-producing adrenocortical tumors, in order to further characterize its expression.
Design and Methods

Ethical Considerations
The protocol for tissue collection and the experimental procedure were approved by the regional ethics committees, and written informed consent was obtained from the patients.
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Adrenocortical tissue materials
Normal adult adrenal tissues (NA) were obtained from patients undergoing expanded nephrectomy for kidney cancer (n=6, sex ratio 1:1). All layers of the adrenal cortex were included in the molecular study, and were histologically normal. Tumor tissues were obtained from 15 adult patients with either an adrenal feminizing tumor (FT, n=2, M/F sex ratio 1:1), a cortisol-producing adenoma associated with overt (CS, n=4, M/F sex ratio:1:3) or subclinical Cushing's syndrome (SCS, n=6, M/F sex ratio 2:1) or an aldosterone-producing adenoma (APA, n=3, M/F sex ratio 0:3). Tumor tissues were obtained by surgery and immediately dissected by the pathologist. Adrenocortical fragments were rapidly frozen and stored at -80°C until enzyme assay or RNA extraction.
Patients
Patient FT1 was a 30-year old male presenting with severe gynecomastia related to a 6 x 5.5 x 5 cm right adrenal tumor secreting estrone and estradiol at plasma concentrations respectively 5-fold and 2.5-fold higher than normal. The clinical and biochemical characteristics of patient FT1 were previously reported (10) . Tumor mass was 100 g, Weiss score staging was 3 (11) and McFarlane-Sullivan staging was II (12) .
Patient FT2 was a 26-year old female presenting with irregular menses, obesity and hirsutism related to a 5-cm left adrenal tumor secreting cortisol (free urinary cortisol 1761 nmol/day, normal range 55-275), testosterone (3.8 nmol/l, normal range 0.347-2.43) and estrogens (estrone 32081 pmol/l, normal range 56-330, estradiol 36000 pmol/l, normal range 30-170).
Tumor mass was 50g, Weiss score staging was 3 and McFarlane-Sullivan staging was I. 17p13 loss of heterozygosity was not found in the tumor tissue.
Patients from CS group exhibited the typical features of Cushing's syndrome and high plasma and urinary cortisol levels together with suppressed plasma ACTH levels. Patients from SCS group had no signs of Cushing's syndrome, normal basal plasma and urinary cortisol levels 
Aromatase activity assay
We used the technique for aromatase activity assay previously described by Conley et al (13) .
Microsomes from each tissue were prepared by successive ultracentrifugations. All 
Aromatase mRNA quantification by RT-PCR
Aromatase transcripts were measured in fragments from adrenal tumors and from four normal human adrenals. Total RNA were isolated according to the usual technique (14) . The cDNAs obtained by retrotranscription with oligodT [12] [13] [14] [15] [16] [17] [18] were amplified using a polymerase chain reaction using the primers described in table 1 Phase contrast electron microscopy allowed the localization of the different structural zonas of the human adrenal cortex.
Statistical Analysis
The enzyme activity and the mRNA levels measured in the different adrenocortical fragments were compared by a non-parametric Mann-Whitney test. Level of significance was p<0.05.
Linear correlation analysis was performed by Spearman test.
Page 7 of 22
Results
Aromatase enzyme activity
Microsomal aromatase activity was detected in NA and in all tumor subtypes. In comparison with NA, the two FT showed high aromatase activity level, with a 7-fold and 40-fold enhancement respectively (Fig.1 ). In comparison with human follicle granulosa cell microsomes, aromatase activity detected in the FT1
(780 fmol/mg prot/h) and FT2 (4656 fmol/mg prot/h) feminizing tumors were respectively 1/35 and 1/6 th (data not shown). Aromatase activity was detected at low level in all NA fragments (mean S.E.M 103 30.5 fmol/mg prot/h), and at comparable level in adrenal samples from the CS, SCS and APA secreting tumors (Fig. 1) .
Quantitative PCR analysis of CYP 19 mRNA
Aromatase mRNA expressed as a ratio to GAPDH mRNA were detected in all samples from aromatase staining sections showed a cytoplasmic localization of aromatase (Fig. 5 A,B) .
Discussion
The present study demonstrates the expression of aromatase in adrenal tissues from the normal gland but also from different adrenocortical tumors. Such expression was detected by two methods, ie enzyme activity and mRNA quantitation by RT-PCR. Estrogen production by the adrenal was suggested from studies performed in the 70's demonstrating the adrenal contribution to circulating estrogens by adrenal vein sampling in normal women and in patients with congenital virilizing adrenal hyperplasia (3, 4, 17) . Cell culture experiments also suggested that normal human adrenal cells may produce estrone in vitro (18) . More recent studies showed the presence of aromatase activity and/or aromatase transcripts in the normal adrenal gland (5,6,9) but such results were not found by others (8, 19) . Aromatase mRNA lacking exon 5 was also identified in normal human adrenal (20) . The present study has
shown the presence of aromatase activity, although at low level, in normal adrenal tissues.
Moreover, immunofluorescence experiments confirmed the presence of aromatase in the cytoplasm of steroidogenic cells from the different adrenocortical zonas, with a stronger expression in the zona reticularis than in both zona fasciculata and zona glomerulosa. We probably reflects a lower degree of differentiation.
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Promoter activity was also characterized in normal adrenocortical tissues and in estrogenproducing tumors. In both, promoter PII was the major transcript while PI.4 was weakly expressed confirming previous studies (8) (9) (10) 19 ).
The present study also questioned the presence of aromatase in adrenal tumors apart from the rare estrogen-producing tumors, which was suggested by studies based on adrenal vein catheterization in aldosterone and cortisol producing tumors (21) . We observed in a set of Cushing's syndrome, possibly due to the much lower level of glucocorticoid excess in the latter.
The physiological role of aromatase in the adrenal remains speculative. Aging is associated with a 2-to 4-fold increase of in vivo androstenedione to estrone conversion in postmenopausal women, and the adrenal gland may play a role in estrogen synthesis and exert some of its protective effects after menopause (26) . Another key question lies in the possible proliferative effect of locally produced estrogens from adrenocortical tumors. Aromatase expression is dramatically enhanced in the stromal cells of female breast carcinoma suggesting that locally synthesized estrogens may act in a paracrine way to promote tumor growth (27) . Beta estrogen receptors were identified in steroid-secreting adrenocortical tumors, and estrogens may thus induce adrenocortical cell proliferation (28) . One may thus speculate on the implication of estrogen receptor expression in adrenocortical tumors, which should favor estrogen-induced proliferation. In this perspective, our study is limited by the small number of tumors which were investigated and by the absence of estrogen receptor quantitation.
In conclusion, our data demonstrate the presence of a functional aromatase enzyme in the normal adrenal gland but also in feminizing-and non feminizing-producing adrenocortical tumors. The differential aromatase expression level and promoter utilization between tumor subtypes suggests complex regulating mechanisms which have to be further analyzed.
